BioGX And Launch Diagnostics Announce Distribution Partnership For U.K. And Ireland

BIRMINGHAM, Ala., Feb. 8, 2018 /PRNewswire/ — BioGX continues to expand its global presence with the announcement of a distribution partnership between BioGX’s Amsterdam-based European subsidiary, BioGX B.V., and U.K.-based distributor, Launch Diagnostics. Read more

BioGX BV And AxonLab AG Announce Distribution Partnership

BIRMINGHAM, Ala., Feb. 6, 2018 /PRNewswire/ — BioGX continues to expand its international presence with the announcement of a new strategic partnership between BioGX’s Amsterdam-based European subsidiary and Switzerland-based distributor, AxonLab AG. Read more

BioGX Launches Four CE-Marked IVD Assays At The European Congress Of Clinical Microbiology And Infectious Diseases (ECCMID)

VIENNA, AUSTRIA, April 24, 2017 /PRNewswire/ — BioGX, a Birmingham Alabama based molecular diagnostics company, announced the launch of four additional CE-IVD infectious disease tests at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), reflecting the inspiring vision of ECCMID: “Managing Infections, Promoting Science”. BioGX has developed an extensive line of multiplex tests for infectious organisms that aid in early diagnosis and proactive management of infections. Read more

Announcing The Establishment Of BioGX EU

BIRMINGHAM, Ala., April 21, 2017 /PRNewswire/ — BioGX, a developer and manufacturer of molecular diagnostics CE-IVD tests has announced the establishment of European operations based in Amsterdam, Netherlands. Read more

BioGX Receives 2017 Governor’s Trade Excellence Award

Montgomery, AL, March 8, 2017 – BioGX was honored as one of eight (8) companies selected as a 2017 Governor’s Trade Excellence Awards recipient during a ceremony at the state Capitol in Montgomery, AL. Read more

BioGX Sample-Ready TM Technology Selected By NASA For Genetic Analysis Aboard The International Space Station

BIRMINGHAM, Ala., November 10, 2016 — BioGX announced its Sample-Ready TM lyophilized qPCR technology was selected by the NASA WetLab-2 program to conduct genetic analysis aboard the International Space Station (ISS). BioGX core technology enables real-time PCR based scientific studies in the microgravity environment of the ISS. Read more

BioGX Receives CE-IVD Mark For Influenza A, B And Respiratory Syncytial Virus Assay On The BD MAX System

BioGX announced it has received CE-IVD marking for its Flu A, Flu B, RSV automated test on Becton, Dickinson and Company’s (BD) BD MAXTM system for detection of Influenza A, B and Respiratory Syncytial Virus (RSV). The test is intended to simultaneously detect the presence of Flu A, Flu B and RSV RNA present in nasopharyngeal swabs samples collected from individuals at risk of infection. Read more

BioGX EcLiSa Test Featured By UNC

The BioGX EcLiSa test is used for testing fresh produce for contaminating bacteria like E. coli, Salmonella, and Listeria. Our work with the University of North Carolina at Chapel Hill has recently been featured in a spotlight article and video titled, “Science for safer food”. CLICK HERE to link to the article.

ARUP GI Presentation

ASM/Microbe 2016: ARUP presents a pivotal poster on assays for Molecular testing of gastrointestinal (GI) pathogens causing acute diarrhea using of BioGX’s Sample Ready technology. Read more

ASM/Microbe 2016: Tampa General

ASM/Microbe 2016: Tampa General presents excellent analytical data on BioGX’s Sample Ready multiplex Flu A, Flu B and RSV on a BD MAXTM open channel assay platform. Read more